$INO Balance Sheet | Understand Stock

$INO

$0.89 +$0.02 (2.32%) Close

$INO Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Balance Sheets

In millions of USD, except per-share amounts

	Q2 FY2026 As of Jun 30, 2026	Q1 FY2026 As of Mar 31, 2026	Q4 FY2025 As of Dec 31, 2025	Q3 FY2025 As of Sep 30, 2025	Q2 FY2025 As of Jun 30, 2025	Q1 FY2025 As of Mar 31, 2025	Q4 FY2024 As of Dec 31, 2024	Q3 FY2024 As of Sep 30, 2024	Q2 FY2024 As of Jun 30, 2024	Q1 FY2024 As of Mar 31, 2024	Q4 FY2023 As of Dec 31, 2023	Q3 FY2023 As of Sep 30, 2023	Q2 FY2023 As of Jun 30, 2023	Q1 FY2023 As of Mar 31, 2023	Q4 FY2022 As of Dec 31, 2022	Q3 FY2022 As of Sep 30, 2022	Q2 FY2022 As of Jun 30, 2022	Q1 FY2022 As of Mar 31, 2022	Q4 FY2021 As of Dec 31, 2021	Q3 FY2021 As of Sep 30, 2021
ASSETS
Current assets:
Cash and cash equivalents
Short-term investments
Accounts receivable from affiliated entity
Nonrelated Party
Related Party
Total accounts receivable from affiliated entity
Accounts receivable from affiliated entities
Prepaid expenses and other current assets, including from affiliated entity
Prepaid expenses and other current assets from affiliated entity
Total current assets

Fixed assets, net
Investments in affiliated entity
Investment in Geneos
Intangible assets, net
Goodwill
Operating lease right-of-use assets
Other assets
Total assets

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable and accrued expenses
Nonrelated Party
Related Party
Total accounts payable and accrued expenses

Accounts payable and accrued expenses due to affiliated entities
Accrued clinical trial expenses
Deferred revenue
Common stock warrant liabilities
Operating lease liability
Grant funding liability, including from affiliated entity
Convertible senior notes
Grant funding liability from affiliated entity
Total current liabilities

Deferred revenue, net of current portion
Convertible senior notes
6.50% Convertible Senior Notes Due 2024
Convertible Bonds
Total convertible senior notes

Operating lease liability, net of current portion
Deferred tax liabilities
Grant funding liability from affiliated entity, net of current portion
Other liabilities
Total liabilities
Stockholders’ equity:
Preferred stock
Common stock
Additional paid-in capital
Accumulated deficit
Accumulated other comprehensive loss
Total Inovio Pharmaceuticals, Inc. stockholders’ equity
Total liabilities and stockholders’ equity

Comments